BioCentury | Jan 23, 2021
Translation in Brief

Ionis’ ASO therapy for MM; plus epigenetic modification prevents myeloma-associated bone loss and bryostatin analogs reduce neuroinflammation

...Golovin, Staff Writer Ionis’ antisense oligonucleotide therapy prevents malignant myeloma regenerationUniversity of California San Diego and Ionis Pharmaceuticals Inc....
...N-methyltransferase 2 IRF4 – Interferon regulatory factor 4PKC – Protein kinase C Danielle Golovin University of California San Diego Ionis Pharmaceuticals Inc. Bellvitge...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...chief commercial officer, and Fromen was most recently global VP of population genomics and precision health.Ionis Pharmaceuticals Inc....
...peers, and sponsorship (MAPS) program and as chair of its Research Triangle Park, N.C., chapter. BC Staff Ionis Pharmaceuticals Pacific...
BioCentury | Jan 6, 2021
Management Tracks

Lin leaving Nektar as CMO; plus HKEX’s Tai named interim CEO, PureTech, Patient Square Capital, Novacyt and more

...Eade joined as general counsel. Dolski was VP, finance at Akcea Therapeutics Inc., which was acquired by Ionis Pharmaceuticals Inc....
BioCentury | Jan 6, 2021
Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

...Capital also participated, along with existing investors, Johnson & Johnson Innovation – JJDC, BioMotiv and Ionis Pharmaceuticals Inc....
...yielding a more homogeneous product than typical antibody conjugation methods.TARGETSTNC (TN) – Tenascin C Karen Tkach Tuzman Ionis Pharmaceuticals Inc. Aro...
BioCentury | Dec 19, 2020
Management Tracks

RNA pioneer Crooke readies to look beyond Ionis

...Amgen Inc. (NASDAQ:AMGN); Leonard Schleifer, founder, president and CEO of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN); and Genzyme Corp.’s Henri Termeer.Like Regeneron, Ionis Pharmaceuticals Inc....
...no cost. He will continue to advise Ionis, including guiding the antisense research group he founded. Jeff Cranmer Ionis Pharmaceuticals Inc. Stanley...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Repeat expansion-targeting antisense oligo for ALS and frontotemporal dementia

...antisense oligo targeting G4C2 repeats —provided by Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

...C9orf72 protein to treat ALS or FTD. Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...antibodies in clinical testing and is partnered with Ionis Pharmaceuticals Inc....
BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

...patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi inotersen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc....
BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...has seen eight new senior management appointments and three internal promotions in less than a year.Ionis Pharmaceuticals Inc....
...Ionis being the most active dealmaker at 18 total deals.TARGETSANGPTL3 – Angiopoietin-like 3 Amanda Micklus Akcea Therapeutics Inc. Ionis Pharmaceuticals Inc. Antisense acquisition...
Items per page:
1 - 10 of 1434
BioCentury | Jan 23, 2021
Translation in Brief

Ionis’ ASO therapy for MM; plus epigenetic modification prevents myeloma-associated bone loss and bryostatin analogs reduce neuroinflammation

...Golovin, Staff Writer Ionis’ antisense oligonucleotide therapy prevents malignant myeloma regenerationUniversity of California San Diego and Ionis Pharmaceuticals Inc....
...N-methyltransferase 2 IRF4 – Interferon regulatory factor 4PKC – Protein kinase C Danielle Golovin University of California San Diego Ionis Pharmaceuticals Inc. Bellvitge...
BioCentury | Jan 8, 2021
Management Tracks

PacBio hires pair of Illumina vets; plus Ionis, Sana, Purespring, eFFECTOR, Constellation, T2, MiNA, Vividion, Pharma Two B and WIB

...chief commercial officer, and Fromen was most recently global VP of population genomics and precision health.Ionis Pharmaceuticals Inc....
...peers, and sponsorship (MAPS) program and as chair of its Research Triangle Park, N.C., chapter. BC Staff Ionis Pharmaceuticals Pacific...
BioCentury | Jan 6, 2021
Management Tracks

Lin leaving Nektar as CMO; plus HKEX’s Tai named interim CEO, PureTech, Patient Square Capital, Novacyt and more

...Eade joined as general counsel. Dolski was VP, finance at Akcea Therapeutics Inc., which was acquired by Ionis Pharmaceuticals Inc....
BioCentury | Jan 6, 2021
Product Development

Propelled by Ionis deal, Aro raises $88M series A to advance targeted oligo pipeline

...Capital also participated, along with existing investors, Johnson & Johnson Innovation – JJDC, BioMotiv and Ionis Pharmaceuticals Inc....
...yielding a more homogeneous product than typical antibody conjugation methods.TARGETSTNC (TN) – Tenascin C Karen Tkach Tuzman Ionis Pharmaceuticals Inc. Aro...
BioCentury | Dec 19, 2020
Management Tracks

RNA pioneer Crooke readies to look beyond Ionis

...Amgen Inc. (NASDAQ:AMGN); Leonard Schleifer, founder, president and CEO of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN); and Genzyme Corp.’s Henri Termeer.Like Regeneron, Ionis Pharmaceuticals Inc....
...no cost. He will continue to advise Ionis, including guiding the antisense research group he founded. Jeff Cranmer Ionis Pharmaceuticals Inc. Stanley...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Repeat expansion-targeting antisense oligo for ALS and frontotemporal dementia

...antisense oligo targeting G4C2 repeats —provided by Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Emerging Company Profile

Libra launches with $29M, three neurodegeneration programs to lower toxic protein levels

...C9orf72 protein to treat ALS or FTD. Ionis Pharmaceuticals Inc....
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...antibodies in clinical testing and is partnered with Ionis Pharmaceuticals Inc....
BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

...patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi inotersen from Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc....
BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

...has seen eight new senior management appointments and three internal promotions in less than a year.Ionis Pharmaceuticals Inc....
...Ionis being the most active dealmaker at 18 total deals.TARGETSANGPTL3 – Angiopoietin-like 3 Amanda Micklus Akcea Therapeutics Inc. Ionis Pharmaceuticals Inc. Antisense acquisition...
Items per page:
1 - 10 of 1434